Dr. Ritu Tiwari
Ministry of Health and Family Welfare
India
Abstract Title: Mpox Outbreak Response: Regulatory and Public Health Perspectives from India and the World
Biography:
Dr. Ritu Tiwari possesses over 28 years of extensive experience in the field of drug analysis, with particular emphasis on pharmacovigilance, phytochemistry, and herbal medicines. She is currently appointed to the Scientific Officer, Pharmacovigilance Division at the Indian Pharmacopoeia Commission, under the Ministry of Health and Family Welfare, Government of India. Throughout her tenure, she has made significant contributions across various divisions, having been affiliated with the Indian Pharmacopoeia since 1998. Dr. Tiwari has authored numerous distinguished research publications focusing on herbal medicines, quality control, and phytopharmaceuticals. Additionally, she serves as a National Accreditation Board for Testing and Calibration Laboratories (NABL) assessor at the national level.
Research Interest:
Monkeypox is a zoonotic viral disease caused by the monkeypox virus. India reported its first confirmed mpox case on July 15, 2022, necessitating an immediate response. The World Health Organisation has declared a global health emergency due to the increase in the number of cases worldwide. The perspective discusses the challenges and strategies to be implemented by Indian and global healthcare systems in dealing with the monkeypox outbreak. This correspondence focuses on the national and international outbreak of the monkeypox virus. It also discusses the recommendations put forward by WHO. It also elaborates on the strategy and steps to be put into action by the government and the citizens of the nation. The recent mpox outbreak has posed challenges to healthcare systems. Therefore, a coordinated approach involving healthcare providers, government organisations, and the public is required to control the mpox outbreak. Further research is needed to understand the virus and develop effective interventions for future outbreaks.